Overview
Carterra provides high-throughput surface plasmon resonance (HT-SPR) platforms like LSA, LSAXT, and Ultra for accelerating monoclonal antibody (mAb) discovery and characterization in pharma and biotech. These systems deliver up to 100x more data in 10% of the time using 1% of sample volumes compared to traditional platforms, enabling kinetics, epitope binning, and analysis of up to 150,000 interactions. They support therapeutic areas including immuno-oncology, infectious diseases, auto-immunity, and vaccines.
Frequently asked questions
- What are the key capabilities of Carterra's HT-SPR platforms?
- Carterra's LSA, LSAXT, and Ultra platforms offer high-throughput kinetics screening, epitope binning, and characterization of up to 1,152 mAbs or 384x384 interactions, with patented microfluidics for minimal sample use and rapid analysis.
- What therapeutic areas does Carterra support?
- Carterra focuses on immuno-oncology/cancer, pain, auto-immunity, heart disease, and infectious diseases/vaccines, with platforms suited for long-term research and rapid response to threats like COVID-19.
- How does Carterra's technology compare to traditional SPR systems?
- Carterra delivers 100x the data in 10% of the time using 1% of sample requirements, enabling single-step high-resolution antibody screening and direct candidate selection within 90 days.